The non-inferiority threshold in the two phase-3 trials is 6% (12% if calculated as two-sided). The trials are powered at 90% to achieve non-inferiority vs Pegasys for at least one of the two Albuferon doses.
The power for showing superiority of at least one dose of Albuferon to Pegasys is closer to 80%.
Market Data 
Markets 
AI
